Presenting author
Ravi Anand
3 presentations
PS02-2242. Design and updates of the phase-3, potentially pivotal, ENIGMA-TRS program: the global study of evenamide in treatment-resistant schizophrenia
PS04-4200. Evenamide in patients with poor response to antipsychotics or treatment-resistance: unique benefits extending to social functioning and life engagement domains
PS04-4236. Do cultural factors and language influence efficacy outcomes? Results from Study 008A in Latin America and Asia